Wednesday, 22 August 2012

Boots Dual Action Athlete's Foot Spray





1. Name Of The Medicinal Product



Dual Action Athlete's Foot Spray


2. Qualitative And Quantitative Composition







Active Ingredient

% quantity

Tolnaftate

0.12 w/w


3. Pharmaceutical Form



Dry Powder Spray



4. Clinical Particulars



4.1 Therapeutic Indications



The product is indicated for the adjunctive treatment and prevention of athlete's foot (tinea pedis). It may also be helpful in conditions where tenderness and sweating cause skin irritation. It is also effective in other conditions, such as dhobie itch (tinea cruris) and prickly heat (miliaria).



4.2 Posology And Method Of Administration



Adults, elderly and children over 2 Years



The affected area should be treated morning and night.



Treatment should continue for at least a week after the infection has cleared up.



Children under 2 Years



Not recommended except under the advice and supervision of a doctor



For topical application to the skin.



4.3 Contraindications



Hypersensitivity to any of the ingredients.



4.4 Special Warnings And Precautions For Use



If irritation or hypersensitivity occurs or if the condition does not improve within 10 days or becomes worse, treatment should be discontinued and medical advice sought.



Avoid contact with eyes.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No clinically significant drug interactions known.



4.6 Pregnancy And Lactation



Safety in pregnancy has not been established. However, no teratogenic effects have been observed in clinical use. In studies in rats and mice, tolnaftate did not exert a deleterious effect on foetal or postnatal development.



If is not known whether topical tolnaftate is secreted into breast milk. However no undesirable effects in breast fed infants whose mothers were using tolnaftate have been reported.



4.7 Effects On Ability To Drive And Use Machines



No adverse effects known.



4.8 Undesirable Effects



Skin reactions occur rarely and may include irritation and contact dermatitis.



4.9 Overdose



Not applicable.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Tolnaftate is an established antifungal agent which appears to produce its effects through inhibition of sterol synthesis.



5.2 Pharmacokinetic Properties



No data available.



5.3 Preclinical Safety Data



There are no preclinical data of relevance to the prescriber which are additional to that already included.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Talc extra 5/0 - M20 DEC



Denatured ethanol B grade



Disteardimonium hectorite



Dimethyl ether



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



24 months.



6.4 Special Precautions For Storage



Store below 25°C.



Caution: Flammable.



Pressurised container, protect from sunlight and do not expose to temperatures exceeding 50°C.



Do not pierce or burn, even after use.



Do not spray on a naked flame or any incandescent material.



Avoid inhalation.



Do not use near, or place container on, polished or painted surfaces. CFC-Free - does not contain CFC's which damage ozone.



6.5 Nature And Contents Of Container



Internally lacquered aluminium can fitted with a continuous spray valve and an actuator.



Pack size: 150 millilitres



6.6 Special Precautions For Disposal And Other Handling



None.



7. Marketing Authorisation Holder



The Boots Company PLC



1 Thane Road West



Nottingham NG2 3AA



8. Marketing Authorisation Number(S)



PL 00014/0520



9. Date Of First Authorisation/Renewal Of The Authorisation



26 April 1996.



10. Date Of Revision Of The Text



June 2001.




No comments:

Post a Comment